3-Methylen-1-cyclobuten | 27538-13-2

• 分子结构分类: 有机化合物 - 碳氢化合物 - 不饱和烃
• 英文名称: 3-Methylen-1-cyclobuten
• 英文别名: 3-methylenecyclobutene；methylenecyclobutene；Methylencyclobuten；methylene-cyclobutene；Methylen-cyclobuten；methylene cyclobutene；3-Methylidenecyclobut-1-ene；3-methylidenecyclobutene
• CAS: 27538-13-2
• 化学式: C₅H₆
• 分子量: 66.1026
• InChiKey: AQSOFHKMDGNCDW-UHFFFAOYSA-N

物化性质

• 熔点：
  37 °C
• 沸点：
  0.0-5.2 °C(Press: 35 Torr)
• 密度：
  0.82±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  5
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  0

反应信息

• 作为反应物：
  描述：

  3-Methylen-1-cyclobuten 在 四氯化碳 、 溴 作用下， 生成 3-bromo-1-bromomethyl-cyclobutene
  参考文献：
  名称：

  小环化合物。十五。亚甲基环丁烯及相关物质1

  摘要：

  亚甲基环丁烯由亚甲基丙二酸二乙酯通过3-亚甲基环丁烷羧酸和3-亚甲基环丁胺合成。该合成的特点是在环丁烷环的丙二酸酯闭合过程中使用蒽作为环外双键的封闭基团。4,4-二甲基-3-亚甲基环丁烯是由α-蒎烯和1-苯基-3-亚甲基环丁烯通过丙二烯与苯乙炔缩合得到的。已发现溴加成和亚甲基环丁烯的三种聚合反应按照基于简单分子轨道理论的预测进行。已经制备了 3-亚甲基三亚甲基氧化物，因为它可能在整个环上具有明显的 π 键合，因此很受关注。

  DOI：

  10.1021/ja01597a040
• 作为产物：
  描述：

  [1.1.1]螺桨烷 以 gas 为溶剂， 反应 0.08h， 生成 3-Methylen-1-cyclobuten
  参考文献：
  名称：

  [1.1.1]Propellane

  摘要：

  DOI：

  10.1021/ja00383a046

文献信息

• Substituted oxidole derivatives as protein tyrosine and as protein serine/threonine kinase inhibitors
  申请人：SmithKline Beecham Corporation

  公开号：US06369086B1

  公开（公告）日：2002-04-09

  The present invention relates generally to novel substituted oxindole compounds and compositions. Such compounds and compositions have utility as pharmacological agents in treating diseases or conditions alleviated by the inhibition or antagonism of protein kinase activated signalling pathways. In particular, the present invention relates to a series of substituted oxindole compounds, which exhibit protein tyrosine kinase and protein serine/threonine kinase inhibition, and which are useful in inhibiting tumor growth via inhibition of such kinases as well as protecting a patient undergoing chemotherapy from chemotherapy induced alopecia.

  本发明总体上涉及新颖的取代吲哚化合物和组合物。这类化合物和组合物作为治疗药物，在治疗通过抑制或拮抗蛋白激酶激活的信号通路而缓解的疾病或状况方面具有效用。特别是，本发明涉及一系列取代吲哚化合物，这些化合物表现出蛋白酪氨酸激酶和蛋白丝氨酸/苏氨酸激酶的抑制作用，并且可用于通过抑制这些激酶来抑制肿瘤生长，以及保护接受化疗的患者免受化疗引起的脱发。
• <b>Small-Ring Compounds. XXXVI. 3-Methylenecyclobutyl Bromide and 1-Methylcyclobut-2-enyl Bromide</b>
  作者：Edgar F. Kiefer、John D. Roberts

  DOI：10.1021/ja00864a021

  日期：1962.3

  3-Methylenecyclobutyl bromide and 1-methylcyclobut-2-enyl bromide have been synthesized from the cycloaddition products of allene with acrylonitrile and vinyl benzoate. The rate constants for solvolysis of the two bromides in aqueous ethanol have been determined and correlated with the solvolysis rates of a series of analogous bromides. 1-Methylcyclobut-2-enyl bromide appears to exhibit some rate enhancement

  由丙二烯与丙烯腈和苯甲酸乙烯酯的环加成产物合成了3-亚甲基环丁基溴和1-甲基环丁-2-烯基溴。两种溴化物在乙醇水溶液中的溶剂分解速率常数已经确定，并与一系列类似溴化物的溶剂分解速率相关联。1-甲基环丁-2-烯基溴化物似乎表现出一定的速率增强，这是由于电子形式上以3-位为中心的交叉环s型相互作用与过渡态中缺电子的1-位。
• Kinetics and Mechanism of the Thermal Rearrangement of [1.1.1]Propellane
  作者：Oliver Jarosch、Robin Walsh、Günter Szeimies

  DOI：10.1021/ja994043v

  日期：2000.9.1

  kinetics of the thermal rearrangement of [1.1.1]propellane (1) have been investigated by gas-phase pyrolysis in a stationary system. The unimolecular reaction leads to dimethylenecyclopropane (2) and its thermal isomerization product ethenylidenecyclopropane (5) with the following Arrhenius parameters: log(A/s-1) = 14.02 ± 0.23; EA/kcal mol-1 = 39.66 ± 0.52. Furthermore, it was shown that the minor

  [1.1.1] 推进剂 (1) 的热重排动力学已通过固定系统中的气相热解进行了研究。单分子反应生成二亚甲基环丙烷 (2) 及其热异构化产物亚乙烯基环丙烷 (5)，其 Arrhenius 参数如下：log(A/s-1) = 14.02 ± 0.23；EA/kcal mol-1 = 39.66 ± 0.52。此外，还表明次要产物亚甲基环丁烯 (3) 及其热异构化产物 1,2,4-戊三烯 (6) 由反应容器表面催化的多相副反应产生。势能面的从头算和 DFT 计算表明异构化遵循异步反应路径，其中涉及 [1.1.1] 推进器 (1) 的两个侧键。CCSD(T)/6-311G(2d,p)//MP2/6-311G(2d,
• Substituted oxindole derivatives as protein tyrosine and as protein serine/threonine kinase inhibitors and compositions and methods of treating chemotherapy and radiation therapy side effects
  申请人：——

  公开号：US20030069430A1

  公开（公告）日：2003-04-10

  Compounds of formula (I): wherein X is N, CH, CCF 3 , or C(C 1-12 aliphatic); R 4 is sulfonic acid, C 1-12 aliphatic-sulfonyl, sulfonyl-C 1-12 aliphatic, C 1-12 aliphatic-sulfonyl-C 1-6 aliphatic, C 1-6 aliphatic-amino, R 7 -sulfonyl, R 7 sulfonyl-C 1-12 aliphatic, R 7 -aminosulfonyl, R 7 aminosulfonyl-C 1-12 aliphatic, R 7 -sulfonylamino, R 7 -sulfonylamino-C 1-12 aliphatic, aminosulfonylamino, di-C 1-12 aliphatic amino, di-C 1-12 aliphatic aminocarbonyl, di-C 1-12 aliphatic aminosulfonyl, di-C 1-12 aliphatic amino, di-C 1-12 aliphatic aminocarbonyl, di-C 1-12 aliphatic aminosulfonyl-C 1-12 aliphatic, (R 8 ) 1-3 -Arylamino, (R 8 ) 1-3 -Arylsulfonyl, (R 8 ) 1-3 -Aryl-aminosulfonyl, (R 8 ) 1-3 -Aryl-sulfonylamino, Het-amino, Het-sulfonyl, Het-aminosulfonyl, aminoiminoamino, or aminoiminoaminosulfonyl, R 5 is hydrogen; and further wherein R 4 and R 5 are optionally joined to form a fused ring, pharmaceutical formulations comprising them and their use in therapy, especially in the treatment of diseases mediated by CDK2 activity, such as alopecia induced by cancer chemotherapy or radiotherapy.

  化合物的公式（I）：其中X为N，CH，CCF3或C（C1-12脂肪族）; R4为磺酸，C1-12脂肪族磺酰基，磺酰基-C1-12脂肪族，C1-12脂肪族磺酰基-C1-6脂肪族，C1-6脂肪族氨基，R7-磺酰基，R7磺酰基-C1-12脂肪族，R7-氨基磺酰基，R7氨基磺酰基-C1-12脂肪族，R7-磺酰胺基，R7-磺酰胺基-C1-12脂肪族，氨基磺酰胺基，二C1-12脂肪族氨基，二C1-12脂肪族氨基甲酰基，二C1-12脂肪族氨基磺酰基，二C1-12脂肪族氨基，二C1-12脂肪族氨基甲酰基，二C1-12脂肪族氨基磺酰基-C1-12脂肪族，（R8）1-3-芳基氨基，（R8）1-3-芳基磺酰基，（R8）1-3-芳基氨基磺酰基，（R8）1-3-芳基磺酰胺基，Het-氨基，Het-磺酰基，Het-氨基磺酰基，氨基亚氨基，或氨基亚氨基磺酰基，R5为氢; 进一步地，其中R4和R5可选择地连接以形成融合环，包括它们的制药配方以及它们在治疗中的应用，特别是在CDK2活性介导的疾病治疗中，例如由癌症化疗或放疗引起的脱发。
• Substituted oxindole derivatives as protein tyrosine kinase and as protein serine/threonine kinase inhibitors
  申请人：SmithKline Beecham Corporation

  公开号：US06541503B2

  公开（公告）日：2003-04-01

  Compounds of formula (I): wherein X is N, CH, CCF3, or C(C1-12 aliphatic); R4 is sulfonic acid, C1-12 aliphatic-sulfonyl, sulfonyl-C1-12 aliphatic, C1-12 aliphatic-sulfonyl-C1-6 aliphatic, C1-6 aliphatic-amino, R7-sulfonyl, R7 sulfonyl-C1-12 aliphatic, R7-aminosulfonyl, R7-aminosulfonyl-C1-12 aliphatic, R7-sulfonylamino, R7-sulfonylamino-C1-12 aliphatic, aminosulfonylamino, di-C1-12 aliphatic amino, di-C1-12 aliphatic aminocarbonyl, di-C1-12 aliphatic aminosulfonyl, di-C1-12 aliphatic amino, di-C1-12 aliphatic aminocarbonyl, di-C1-12 aliphatic aminosulfonyl-C1-12 aliphatic, (R8)1-3-Arylamino, (R8)1-3-Arylsulfonyl, (R8)1-3-Aryl-aminosulfonyl, (R8)1-3-Aryl-sulfonylamino, Het-amino, Het-sulfonyl, Het-aminosulfonyl, aminoiminoamino, or aminoiminoaminosulfonyl, R5 is hydrogen; and further wherein R4 and R5 are optionally joined to form a fused ring, pharmaceutical formulations comprising them and their use in therapy, especially in the treatment of diseases mediated by CDK2 activity, such as alopecia induced by cancer chemotherapy or radiotherapy.

  公式（I）的化合物：其中X为N，CH，CCF3或C（C1-12脂肪族）; R4为磺酸，C1-12脂肪族磺酰基，磺酰-C1-12脂肪族，C1-12脂肪族磺酰基-C1-6脂肪族，C1-6脂肪族氨基，R7磺酰基，R7磺酰基-C1-12脂肪族，R7-氨基磺酰基，R7-氨基磺酰基-C1-12脂肪族，R7-磺酰基氨基，R7-磺酰基氨基-C1-12脂肪族，氨基磺酰基氨基，二C1-12脂肪族氨基，二C1-12脂肪族氨基甲酰基，二C1-12脂肪族氨基磺酰基，二C1-12脂肪族氨基，二C1-12脂肪族氨基甲酰基，二C1-12脂肪族氨基磺酰基-C1-12脂肪族，（R8）1-3-芳基氨基，（R8）1-3-芳基磺酰基，（R8）1-3-芳基氨基磺酰基，（R8）1-3-芳基磺酰氨基，Het-氨基，Het-磺酰基，Het-氨基磺酰基，氨基亚胺基氨基或氨基亚胺基磺酰基，R5为氢; 另外，R4和R5可选择性地结合形成融合环，包括它们的制药配方及其在治疗中的用途，特别是在治疗由CDK2活性介导的疾病，如由癌症化疗或放疗引起的脱发中的应用。